Are a high-refined carbohydrate diet and the alterations resulting from its intake linked to small intestine changes?

Ab­b­Vie’s Skyrizi has demon­strat­ed sig­nif­i­cant­ly high­er rates of steroid-free clin­i­cal and en­do­scop­ic re­mis­sion ver­sus ri­val John­son & John­son’s Ste­lara in a Phase III tri­al, help­ing

GSK’s Blenrep in com­bi­na­tion with two oth­er med­i­cines cut the risk of dis­ease pro­gres­sion or death by 59% com­pared to a stan­dard com­bi­na­tion for mul­ti­ple